Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SODIUM AMINOSALICYLATE vs INH
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Sodium aminosalicylate inhibits folic acid synthesis in Mycobacterium tuberculosis by competing with para-aminobenzoic acid (PABA) for the enzyme dihydropteroate synthase, thereby blocking bacterial growth.
INH inhibits Inh A, an enoyl-acyl carrier protein reductase involved in mycolic acid synthesis, essential for the mycobacterial cell wall. It also disrupts NAD and NADH metabolism via the Kat G-activated isonicotinoyl-NAD adduct.
Tuberculosis (second-line therapy, in combination with other antituberculous agents)
First-line treatment and prophylaxis of tuberculosis (TB) caused by Mycobacterium tuberculosis
4 g orally three times daily (total daily dose 12 g) for tuberculosis treatment. Also available as 10 g in 250 m L for intravenous infusion over 5-6 hours, typically once daily.
300 mg orally once daily (or 15 mg/kg orally once daily, up to 300 mg total) for active tuberculosis; for latent tuberculosis, 300 mg orally once daily or 900 mg orally twice weekly under directly observed therapy.
0.75-1.5 hours (parent drug); prolongs to 4-6 hours in renal impairment or with probenecid coadministration. Rapid acetylation phenotype reduces half-life by ~30%.
Fast acetylators: 0.5-1.5 hours; slow acetylators: 2-4 hours. Clinically, slow acetylators have higher risk of peripheral neuropathy and hepatotoxicity.
Hepatic acetylation (N-acetyltransferase) and renal excretion of metabolites.
Primarily hepatic via N-acetyltransferase 2 (NAT2); also metabolized by cytochrome P450 (CYP2E1) to hepatotoxic metabolites.
Renal: >80% as metabolites (acetylated and free), with 50-60% as N-acetyl-4-aminosalicylic acid; biliary/fecal: <1%.
Renal: 75-95% as unchanged drug and metabolites (including acetylisoniazid, isonicotinic acid). Biliary/fecal: minor (<5%).
50-60% bound to albumin; binding is saturable at high concentrations.
0-10% (low binding; primarily albumin).
0.2-0.3 L/kg (distributes into total body water; low tissue penetration except inflamed pleural fluid and caseous granulomas).
0.6-0.8 L/kg (distributes into total body water, including cerebrospinal fluid and tuberculous cavities).
Oral: 90-100% (rapidly absorbed from GI tract); no parenteral formulation available.
Oral: ~90%. Intramuscular: ~100%.
For GFR <30 m L/min: reduce dose to 4 g orally twice daily (total 8 g/day). For GFR <10 m L/min: administer 4 g orally once daily. No adjustment for GFR ≥30 m L/min.
In patients with GFR < 30 m L/min, reduce dose to 200 mg daily or 300 mg three times weekly. For GFR 30-50 m L/min, no adjustment necessary. For GFR < 10 m L/min, consider 150 mg daily or 300 mg twice weekly.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: consider 50% dose reduction. Child-Pugh Class C: use with caution; consider further reduction or alternative therapy as pharmacokinetics are not well studied.
In Child-Pugh class A, no adjustment. In Child-Pugh class B, reduce dose to 200 mg daily. In Child-Pugh class C, use 150 mg daily or avoid if severe hepatic impairment.
Children: 150-300 mg/kg/day orally divided into 3-4 doses, not to exceed 12 g/day. Intravenous: 150-200 mg/kg/day as a continuous infusion or in divided doses.
10-15 mg/kg orally once daily (max 300 mg) for active tuberculosis; for latent tuberculosis, 10-15 mg/kg orally once daily (max 300 mg) or 20-40 mg/kg orally twice weekly (max 900 mg per dose).
Start at lower end of dosing range (e.g., 4 g orally twice daily) due to age-related decline in renal function. Monitor renal function and adjust per GFR-based guidelines. Caution with hepatic impairment.
No specific dose adjustment required, but monitor for hepatotoxicity and peripheral neuropathy, especially in patients with comorbidities or polypharmacy.
None.
Severe and sometimes fatal hepatitis (especially in patients >35 years, daily alcohol users, and those with pre-existing liver disease); monitor hepatic function closely.
May cause hepatotoxicity, hypersensitivity reactions (fever, rash, eosinophilia), gastrointestinal intolerance, and crystalluria. Monitor liver function tests and renal function periodically.
Hepatotoxicity (monitor LFTs, discontinue if signs of hepatitis),Peripheral neuropathy (pyridoxine prophylaxis recommended),CNS effects (seizures, psychosis; avoid in active CNS disease),Lupus-like syndrome,Drug interactions (e.g., carbamazepine, phenytoin)
Hypersensitivity to aminosalicylic acid or any component; severe renal impairment (Cr Cl < 10 m L/min).
Acute liver disease,History of INH-induced hepatotoxicity,Previous severe adverse reaction (e.g., drug fever, arthritis)
Take with or after meals to minimize gastrointestinal irritation. Avoid alcohol due to increased risk of hepatotoxicity and GI upset. No specific food interactions; but a low-fat diet may help reduce GI side effects.
Foods high in tyramine (e.g., aged cheese, cured meats, soy products) may rarely cause hypertensive crisis in patients also taking MAOIs, though interaction is less significant with INH alone. High-fat meals may delay absorption, so avoid fatty foods near dosing time. No specific dietary restrictions beyond taking on empty stomach.
FDA Pregnancy Category C. First trimester: Limited data; animal studies show some teratogenicity at high doses; no adequate human studies; use only if clearly needed. Second and third trimesters: No specific known fetal risks; however, theoretical risk of kernicterus due to bilirubin displacement from albumin binding, though not confirmed with aminosalicylic acid.
INH (isoniazid) is not known to be a major teratogen. In first trimester, risk of malformations is not significantly increased. In second and third trimesters, there is a potential for hepatotoxicity and peripheral neuropathy, and possibly increased risk of neonatal hemorrhage due to vitamin K deficiency.
Excretion into breast milk is unknown; due to potential for serious adverse reactions in nursing infants (e.g., hypersensitivity, gastrointestinal disturbance), decision should be made to discontinue nursing or the drug, taking into account importance of drug to mother.
INH is excreted into breast milk in low concentrations (M/P ratio approximately 1.6). Breastfeeding is generally considered safe, but monitor infant for signs of peripheral neuropathy or liver toxicity. The American Academy of Pediatrics considers INH compatible with breastfeeding.
No established dose adjustment guidelines for pregnancy; pharmacokinetic changes (increased volume of distribution, increased renal clearance) may theoretically reduce serum concentrations; therapeutic drug monitoring is not routinely recommended but may be considered if efficacy is in question.
No dose adjustment is routinely required for pregnancy. However, due to increased clearance (30-50% higher), some experts recommend monitoring serum INH levels and adjusting dose to maintain therapeutic levels. Pyridoxine supplementation (25-50 mg/day) is recommended to prevent peripheral neuropathy.
Sodium aminosalicylate (PAS) is a bacteriostatic agent used in combination therapy for multidrug-resistant tuberculosis. Administer with or after meals to reduce gastrointestinal upset. Monitor liver function tests and renal function periodically. Watch for hypersensitivity reactions, including fever, rash, and eosinophilia. Use with caution in patients with glucose-6-phosphate dehydrogenase deficiency due to risk of hemolytic anemia.
Administer on an empty stomach (1 hour before or 2 hours after meals) to maximize absorption. Monitor liver function tests (ALT, AST) at baseline and monthly during therapy. Pyridoxine (vitamin B6) 25-50 mg/day should be co-administered to prevent peripheral neuropathy. Hepatotoxicity risk increases with age, alcohol use, and concurrent use of other hepatotoxic drugs. Slow acetylators are more prone to toxicity. Patients with liver disease require careful monitoring and dose adjustment.
Take this medication with or after food to reduce stomach upset.,Do not skip doses or stop taking this medication without consulting your doctor.,Report any signs of allergic reaction such as rash, fever, or swelling.,Avoid alcohol while taking this medication.,Keep all appointments for blood tests to monitor liver and kidney function.,Contact your doctor if you experience nausea, vomiting, abdominal pain, or yellowing of skin or eyes.
Take on an empty stomach with a full glass of water.,Do not drink alcohol while taking this medication due to increased risk of liver damage.,Report immediately any signs of liver problems: dark urine, yellowing of skin or eyes, persistent nausea, or abdominal pain.,Take vitamin B6 as prescribed to prevent numbness or tingling in hands and feet.,Complete full course of therapy even if you feel better to prevent resistance.,Avoid antacids within 1 hour of taking this medication as they may reduce absorption.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SODIUM AMINOSALICYLATE vs INH, answered by our medical review team.
SODIUM AMINOSALICYLATE is a Antitubercular Agent that works by Sodium aminosalicylate inhibits folic acid synthesis in Mycobacterium tuberculosis by competing with para-aminobenzoic acid (PABA) for the enzyme dihydropteroate synthase, thereby blocking bacterial growth.. INH is a Antitubercular Agent that works by INH inhibits Inh A, an enoyl-acyl carrier protein reductase involved in mycolic acid synthesis, essential for the mycobacterial cell wall. It also disrupts NAD and NADH metabolism via the Kat G-activated isonicotinoyl-NAD adduct.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SODIUM AMINOSALICYLATE and INH depend on the specific clinical indication. These are both Antitubercular Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SODIUM AMINOSALICYLATE is: 4 g orally three times daily (total daily dose 12 g) for tuberculosis treatment. Also available as 10 g in 250 m L for intravenous infusion over 5-6 hours, typically once daily.. The standard adult dose of INH is: 300 mg orally once daily (or 15 mg/kg orally once daily, up to 300 mg total) for active tuberculosis; for latent tuberculosis, 300 mg orally once daily or 900 mg orally twice weekly under directly observed therapy.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SODIUM AMINOSALICYLATE and INH in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SODIUM AMINOSALICYLATE is classified as Category C. FDA Pregnancy Category C. First trimester: Limited data; animal studies show some teratogenicity at high doses; no adequate human studies; use only if clearly needed. Second and th. INH is classified as Category C. INH (isoniazid) is not known to be a major teratogen. In first trimester, risk of malformations is not significantly increased. In second and third trimesters, there is a potential. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.